Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Londo who wrote (2490)	1/7/2001 4:06:14 PM
From: smh	Respond to of 52153

<Another one I thought that could be added to your list is that Incyte owns 19.8% of Diadexus, which is apparantly trying to go public. This holding will get diluted after the IPO, if it occurs. No clue to what a potential valuation should be.> Londo, Thanks for the suggestion. I, at least, have overlooked INCY for inclusion in Cross portfolio... not so in my personal one. However, my guess is that INCY's stake in diaDexus is <5% of INCY MC. I also think that INCY is very undervalued for completely separate reasons. Therefore, I am not inclined to include it. Comments anyone? SMH